CD2 and bacterial vaginosis: rhamnosus (Lcr35), Lactobacillus brevis CD2, Lactobacillus salivarius FV2, Lactobacillus acidophilus KS400 and Lactobacillus plantarum FV9 have been used orally or intravaginally in the treatment of bacterial vaginosis (BV) (65, 66) and gastrointestinal disorders as they can improve urogenital and gastrointestinal health through immune modulation, pathogen displacement, and establish an environment less conducive to proliferation of pathogens and virulence factors (66).